tbuckley/cabot-search huggingface dataset:
Genetic profiling of circulating tumor cells in patients with advanced colorectal cancer.
Authors: D. Ernst, I. Kubisch, A. de Albuquerque, S. Kaul, J. Boese-Landgraf, N. Fersis
Journal: Journal of Clinical Oncology (2010)

e14113 Background: We have developed a new preanalytical enrichment method for circulating carcinoma cells (CTC) based on EpCAM and MUC1 specific antibodies coupled to immunomagnetic beads. Molecular detection and tumor cell characterization was performed with a multimarker panel by real-time RT-PCR. Here we present first results of a universal marker panel for local advanced and/or metastatic colorectal cancer. Methods: The high affinity antibodies BM7 (MUC-1) and VU1D9 (EpCAM) were used for immunomagnetic tumor cell enrichment from 10 ml peripheral EDTA-blood of patients with documented metastatic and/or local advanced disease. Separated cells were lysed and used for mRNA isolation and c-DNA synthesis. Real-time quantitative RT-PCR approaches with SYBR assays (Eurogentec) and FAM-labeled TaqMan probes selected with the UniversalProbeLibrary system (Roche AG, Basel, CH) were developed for the epithelial markers cytokeratin 19 and 20 (CK19/20), EpCAM, CEA, Survivin, metastasis associated in colon cancer (MACC) and HIF-1alpha. Results: Sensitivity of the the multimarker panel was validated in calibration tests with 2 and 10 cultured carcinoma cells (embedded tumor cell calibrators, ETC) and the specificity of the panel was confirmed by examination of blood from healthy donors. Positivity rate of ETC controlled real-time RT-PCR on the basis of the multimarker panel was 70% (32 of 46 patients) with local advanced and/or metastatic disease. The marker with the highest prevalence was EpCAM (52%) followed by Survivin (32%), MUC-1 (24%), CK19 (24%), HIF-1 (31%) MACC (15%) and CEA 14%. Conclusions: We have used embedded tumor cells (ETC) as internal calibrators for accurate process control and normalization of the immunobead quantitative RT-PCR technique. The newly introduced surrogate marker panel is linked to cellular characteristics as apoptosis, invasion, angiogenesis and stem cell phenotype. Therefore it may help to give additional information on prognosis and therapy response. It can be used in patient follow-up to detect early metastasis. It also might lead to both tailored therapy regimes and revised indications for adjuvant treatment, independent of lymph node involvement. No significant financial relationships to disclose.
A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis
Authors: Giovanni Palladini, Sajitha Sachchithanantham, Paolo Milani, Julian D Gillmore, Andrea Foli, Philip N Hawkins, Giampaolo Merlini, Ashutosh D Wechalekar
Journal: Blood (2014)
International Clinical Practice Guidelines for the Treatment and Prophylaxis of Thrombosis Associated with Central Venous Catheters in Patients with Cancer
Authors: Debourdeau Philippe, Farge Dominique, Beckers Marielle, Caroline Baglin, Rupert Bauersachs, Benjamin Brenner, Dialina Brilhante, Anna Falanga, Grigoris T Gerotziafas, Nissim Haim, Ajay Kakkar, Alok A. Khorana, Ramon Lecumberri, Mario Mandala, Michel Marty, Manuel Monreal, Shaker S Mousa, Simon Noble, Ingrid Pabinger, Paolo Prandoni, Martin Prins, Mohammed H. Qari, Michael B. Streiff, Konstantin Syrigos, Harry Roger Buller, Henri Bounameaux
Journal: Blood (2012)
Prognostic value of hedgehog signaling in cervical carcinoma.
Authors: N. Chaudary, R. P. Hill, M. Pintilie, D. W. Hedley, A. W. Fyles, M. Milosevic, H. Mackay
Journal: Journal of Clinical Oncology (2010)

e15522 Background: The hedgehog (Hh) pathway is an attractive therapeutic target. Dysregulation of the Hh pathway is implicated in carcinogenesis and tumor progression via maintenance of the cancer stem cell population and paracrine signalling. Hh ligands (SHH/IHH), PTCH1, SMO, Gli1, have little or no expression in normal cervical epithelium whereas increased expression is reported in cervical carcinomas. The tumor microenvironment influences disease progression and treatment response in cervical cancer, with tumor hypoxia and raised interstitial fluid pressure (IFP) associated with poor disease free survival (DFS). The aim of this study was to measure gene expression levels of Hh genes in cervical tumors and correlate these with clinicopathological variables, tumor pO2 (HP5), IFP and DFS. Methods: Frozen biopsies from 91 patients (> 70% tumor) with cervical carcinoma (25 pts stage IB; 2-IIA; 41-IIB; 22-IIIB; 1-IV) were examined for SHH, IHH, PTCH1/2, SMO, and Gli1 expression using quantitative RT-PCR. Prospectively collected clinicopathological, tumor pO2 and IFP data were available for all patients. Results: Heterogeneous gene expression of SHH, IHH, PTCH1/2, SMO and Gli was seen in the patient samples. There was no association between individual Hh gene expression levels nor between individual Hh and tumor size and age (Spearman correlation coefficients < 0.2). Nodal status was weakly associated with PTCH2 (p = 0.05) and FIGO stage with SMO (p = 0.06). There was no association between Hh genes and tumor hypoxia (pO2 and CAIX) or IFP (strongest correlation = 0.37) but SHH (p = 0.03) and Gli1 (p = 0.01) were associated with tumor stromal subclassification. There was a trend towards an association between positive nodal status and IHH (p = 0.07) but no association between Hh gene expression and DFS. Conclusions: Our data suggest that, although members of the Hh pathway are expressed in cervical cancer, there is limited correlation with tumor microenvironment and no correlation with DFS. Evaluation of Hh signalling is complex and may be cancer stage dependent, further investigation is required. No significant financial relationships to disclose.
Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL).
Authors: Luis F. Porrata, Kay M. Ristow, Thomas M Habermann, Thomas E. Witzig, Joseph P. Colgan, David J. Inwards, Stephen M Ansell, Ivana N. Micallef, Patrick B. Johnston, Grzegorz S. Nowakowski, Carrie A. Thompson, Svetomir N. Markovic
Journal: Blood (2012)
Safety and Efficacy of Nilotinib (NIL) in Patients (Pts) with Chronic Phase (CP) or Accelerated Phase (AP) Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib Mesylate (IM): Results from the Multicenter, Observational NOVEL Study in Taiwan
Authors: Ching-Yuan Kuo, Po-Nan Wang, Wen Li Hwang, Cheng-Hwai Tzeng, Li-Yuan Bai, Jih-Luh Tang, Ming-Chih Chang, Sheng-Fung Lin, Tsai-Yun Chen, Yeu-Chin Chen, Tran-Der Tan, Chih-Yi Hseih, Chinjune Lin, Miljkovic Darko, Chang Cheng-Shyong
Journal: Blood (2015)
STAT3 Activation Is Preceded By Two Independent Pathways (BCR-BTK and IL6-JAK) in Mantle Cell Lymphoma
Authors: Hyebin Park, Donglu Zhao, George Tsourdinis, Zhishuo Ou, Archito T. Tamayo, Richard J. Ford, Bingliang Fang, Lan V Pham, Liang Zhang, Michael Wang
Journal: Blood (2014)
Eliminating Routine Glucometer Readings in the Office Setting
Authors: James L. Wofford, Melanie J. Martin, Claudia L. Campos
Journal: JAMA Internal Medicine (2016)

able Care Act were crafted to shed light on physician and hospital interactions with industry.However, a critical gap is that it does not capture payments made to other health care professionals that may also influence, both directly or indirectly, purchasing decisions that are made for pharmaceuticals or medical devices.Senators Chuck Grassley (R-Iowa) and Richard Blumenthal (D-Connecticut) have recently introduced the Provider Payment Sunshine Act (S. 2153) that would partially expand the Sunshine provisions to include other prescribing professionals, eg, nurse practitioners and physician assistants. 9 Based on Grundy's study, and what is revealed by the Massachusetts data, it is clear that even the Provider Payment Sunshine Act does not go far enough.All nurses, in addition to the myriad of professionals that are included in the Massachusetts reporting regulations, should be covered under the Provider Payment Sunshine Act or related legislation.In the United States, the pharmaceutical and medical device industries have fashioned a remarkable web of influence with strands that capture more than just the obvious players-that is, physicians.This web reaches a wide cadre of health care professions and risks accumulating conflicts of interest into every corner of our health care system.However, without inclusion in transparency policies and reporting mechanisms, it is difficult if not impossible to say what influence industry has on nurses and other health care professionals.One can assume it is at least worth the cost of a dinner.
Authors’ reply to Ramachandran
Authors: William Fleischman, Joseph S Ross, Shantanu Agrawal
Journal: BMJ (2016)

Prompted by the recently proposed US amendment S.2978 to exempt from mandatory reporting through the Open Payments program any payments from drug manufacturers to physicians related to physician education,1 Ramachandran asks whether we conducted analyses examining the association between prescribing and any payments related to educational materials.2 3

In response, we performed a subgroup analysis focused on payments for continuing medical education (CME) speaker fees and for educational materials, including journal articles and …
Heart T2* for Prediction of Cardiac Complications in Well-Treated TM Patients
Authors: Alessia Pepe, Antonella Meloni, Giuseppe Rossi, Paolo Cianciulli, Anna Spasiano, Domenico D'Ascola, Aurelio Maggio, Domenico Maddaloni, Antonella Carollo, Michele Rizzo, Ketty Perrotta, Giuseppina Secchi, Maria Eliana Lai, Vincenzo Positano, Massimo Lombardi
Journal: Blood (2011)
Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells
Authors: Natalia M Tijaro-Ovalle, Shuli Li, Zachariah Defilipp, Ioannis Politikos, Robin M. Joyce, Philippe Armand, Vincent T. Ho, John Koreth, Sarah Nikiforow, Edwin P. Alyea, David E. Avigan, Jacalyn Rosenblatt, Jami Brown, Steven McAfee, Bimalangshu Dey, Areej El-Jawahri, Thomas Spitzer, Yi-Bin Chen, Robert J. Soiffer, Joseph H. Antin, Karen K. Ballen, Corey S. Cutler, Jerome Ritz, Vassiliki A Boussiotis
Journal: Blood (2019)
Sensitive Detection of c-kit Point Mutations by D-HPLC in Peripheral Blood and Bone Marrow Samples from Patients with Systemic Mastocytosis.
Authors: Stephanie Lauber, Martin C. Mueller, Philipp Erben, Thomas Schenk, Jens Kruth, Georgia Metzgeroth, Thomas Ernst, Peter Paschka, Rudiger Hehlmann, Andreas Reiter, Andreas Hochhaus
Journal: Blood (2006)
Seven-year follow-up of preoperative chemoradiotherapy in superior sulcus tumor: Report of a Japan Clinical Oncology Group Trial (JCOG9806).
Authors: M. Tsuboi, H. Kunitoh, T. Shibata, H. Asamura, Y. Ichinose, N. Katakami, K. Nagai, T. Mitsudomi, A. Matsumura, N. Saijo
Journal: Journal of Clinical Oncology (2010)

7025 Background: We previously reported (J Clin Oncol 2008) the safety and efficacy of preoperative chemoradiotherapy followed by surgical resection in superior sulcus tumor (SST). Seven-year follow-up data are presented. Methods: Pathologically documented non-small cell lung cancer (NSCLC) patients (pts) with invasion to the first rib or more superior chest wall were eligible. Those with distant metastasis, pleural dissemination or mediastinal node involvements were excluded. Pts received 2 cycles of MVP chemotherapy q 4weeks; mitomycin C 8mg/m2 on day 1, vindesine 3mg/m2 on days 1 and 8, and cisplatin 80mg/m2 on day 1. Radiotherapy, 45Gy/27fr. with 1 week split, to the tumor and ipsilateral supraclavicular nodes was started on day 2. Patients went on to thoracotomy 2-4 weeks after completion of the chemoradiotherapy, or received boost radiotherapy. Results: From May/99 to Nov/02, 76 patients were entered. Seventy five were fully assessable. As of Nov/09, all patients were followed-up for 7 years. Forty-one patients died: 31 (76%) due to NSCLC, 3 (7%) to treatment-related adverse events, 5 (12%) to other causes, and 2 (5%) to unknown causes. The median overall survival (OS) was 7.61 years, with 5- and 7-year OS rate of 56 and 52%, respectively. OS according to background characteristics is summarized in the table. Five- and 7-year OS rates of pts with (N=51) or without (N=24) pathologic complete resection (R0) were 71% and 67%, and 25% and 21%, respectively. Seven-year OS rate of the pts with pathologic complete response (N=12) was 92%. The median progression-free survival (PFS) was 2.31 years, with 5- and 7-year PFS rate of 45% and 44%, respectively. Conclusions: The efficacy of this trimodality approach in patients with SST were confirmed by 7-year follow-up data. OS according to baseline factors Clinical factor MST (year) OS at 5-year OS at 7-year p value c-T3 (n=55) Not reached 62 60 0.0048 c-T4 (n=20) 2.26 40 30 c-N0 (n=58) 6.34 53 50 0.3831 c-N1-3 (n=17) 9.18 65 59 Sq (n=27) 8.42 59 59 0.4394 Non-sq (n=48) 5.65 54 48 # Two-sided log-rank test, unadjusted for multiplicity. No significant financial relationships to disclose.
Dc-based immunotherapy for relapsed high-grade glioma: clinical update of cohorts A,B,C, and D from the cohort comparison trial HGG-Immuno-2003
Authors: Steven De Vleeschouwer, Hilko Ardon, Stefan Rutkowski, Eckhart Kaempgen, J Wolff, Sabine Wagner, Christof Kramm, Frank Van Calenbergh, Stefaan Van Gool
Journal: Neuro-Oncology (2008)
Lumen restoration of long esophageal strictures. Should we shift towards endoscopic submucosal dissection?
Authors: Georgios Mavrogenis, Tom Moreels, Jean-Baptiste Chevaux, Maximilien Thoma, Pierre Deprez, Hubert Piessevaux
Journal: Endoscopy (2016)

We read with interest the article by Gonzalez et al. [1] on the management of complete esophageal strictures secondary to radiation, caustic ingestion, and iatrogenic esophageal stripping. In three of the nine patients, the stricture was long (> 5 cm), including one case with esophageal obstruction of the entire esophagus. In this latter case, the authors successfully applied a multimodal approach, including an initial partial recanalization with the help of a catheter loaded over a guidewire, surgical reconstruction of the upper esophageal sphincter, and in a third session, placement of a metal stent. Shorter strictures were managed with similar techniques, as well as with puncture using a 19-gauge endoscopic ultrasound fine-needle aspiration needle, under fluoroscopic guidance and transillumination.
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials
Authors: Alexandra B. Kimball, Thomas Luger, Alice Gottlieb, Luis Puig, Roland Kaufmann, Enkeleida Nikaï, Baojin Zhu, Emily Edson-Heredia, Hilde Carlier, Chen-Yen Lin, Orin Goldblum, Gil Yosipovitch
Journal: Journal of the American Academy of Dermatology (2016)
Characteristics of Children Aged &lt;18 Years with Zika Virus Disease Acquired Postnatally — U.S. States, January 2015–July 2016
Authors: Alyson B. Goodman, Eric J. Dziuban, Krista Powell, Rebecca H. Bitsko, Gayle Langley, Nicole Lindsey, Jessica L. Franks, Kate Russell, Sharoda Dasgupta, Wanda D. Barfield, Erika Odom, Emily Kahn, Stacey Martin, Marc Fischer, J. Erin Staples
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Zika virus is an emerging mosquito-borne flavivirus that typically causes an asymptomatic infection or mild illness, although infection during pregnancy is a cause of microcephaly and other serious brain abnormalities. Guillain-Barré syndrome and other neurologic complications can occur in adults after Zika virus infection. However, there are few published reports describing postnatally acquired Zika virus disease among children. During January 2015-July 2016, a total of 158 cases of confirmed or probable postnatally acquired Zika virus disease among children aged <18 years were reported to CDC from U.S. states. The median age was 14 years (range = 1 month-17 years), and 88 (56%) were female. Two (1%) patients were hospitalized; none developed Guillain-Barré syndrome, and none died. All reported cases were travel-associated. Overall, 129 (82%) children had rash, 87 (55%) had fever, 45 (29%) had conjunctivitis, and 44 (28%) had arthralgia. Health care providers should consider a diagnosis of Zika virus disease in children who have an epidemiologic risk factor and clinically compatible illness, and should report cases to their state or local health department.
Genetic Randomization to Allogeneic Bone Marrow Transplant in First Remission Pediatric Acute Myeloid Leukemia Patients, Pediatric Oncology Group 9421 (Now Childrens Oncology Group).
Authors: Kimo Stine, David Becton, Gary Van Houten Dahl, Yaddanapudi Ravindranath, Susana C. Raimondi, Fred G. Behm, Myron Chang, Howard Weinstein
Journal: Blood (2004)
P0691 : Knockdown of lysophosphatidylcholine acyltransferase 1 (LPCAT1) increases both the secretion of very-low-density lipoproteins (VLDL) and the infectivity of hepatitis C virus (HCV)
Authors: M. Lemasson, F. Beilstein, V. Pène, A.R. Rosenberg, S. Demignot
Journal: Journal of Hepatology (2015)
A randomized trial of chemoradiotherapy versus surgery alone in patients with resectable esophageal cancer
Authors: H. Carstens, M. Albertsson, S. Friesland, G. Adell, G. Frykholm, G. Wagenius, H. E. Myrvold, I. Farago, D. Stockeld
Journal: Journal of Clinical Oncology (2007)

4530 Background: The aim of this study was to compare survival in a randomized phase III trial of chemoradiotherapy (CHRT) versus surgery alone for localized resectable oesophageal cancer. Methods: Between 2000 and 2004, 91 patients with oesophageal cancer were enrolled in a Scandinavian multicenter study. Patients with resectable oesophageal squamous cell carcinoma (50%) or adenocarcinoma (50%) were randomized to chemoradiotherapy (CHRT) or surgery alone. Chemotherapy (CHT) was given in 3 cycles with cisplatin 100 mg/m 2 , day 1 and 5-fluorouracil 750 mg/m 2 /24 hours, infusion day 1–5, every three weeks. After one induction chemotherapy course, radiotherapy including the primary tumour and defined locoregional lymph nodes, was given concomitant with the following CHT cycles, to a total dose of 64 Gy, in 32 fractions. Surgery was performed according to Ivor Lewis and lymph nodes resected with standard two-field technique. Results: At a median follow-up of 51.8 month’s 65 deaths are noted. In the chemoradiation group 50% of the patients accomplished therapy according to protocol, 40% were treated with modifications of the protocol and radical resection was performed 76% of the patients. Median survival was 12.8 months for chemoradiation and 15.8 months for the surgery group. There was no significant difference in 1-year survival 56% and 55% for CHRT and surgery, respectively. By two years, survival curves diverge and 2-years survival was 37% (CI 95%: 23–51%) for the CHRT group and 25% (CI 95%: 12–39%) for the surgery group. At four years, survival was 29% for CHRT versus 23% for surgery (CI 95% CHRT: 16–43%, CI 95% Surgery: 10–36%). Both treatments were well tolerated and no treatment related deaths were recorded in any of the treatment arms. Most deaths were due to tumor disease (66%) in both groups. Conclusions: No statistically significant differences between the treatment arms were seen and survival results are equal to earlier reported. Both treatment arms were well tolerated. No significant financial relationships to disclose.
Adverse events in non-AIDS-defining cancer patients receiving chemotherapy and combined antiretroviral therapy.
Authors: Sonia Sandhu, Kamila Cisak, Shylandra B. Sreenivasappa, Kumar Kunnal Batra, Shweta Gupta, Michael Russell Mullane, Jennifer Blumetti, Paul G. Rubinstein
Journal: Journal of Clinical Oncology (2013)

e12523 Background: From 1991 to 2005, the number of cases of non-AIDS defining cancers (NADC) rose from 3,192 to 10,059 in the USA. Studies have shown an improvement in survival for many HIV-associated malignancies in the post HAART era. Drug-drug interactions between HIV therapy and chemotherapy (CTX) are not well understood. HIV medications can inhibit or induce the cytochrome p450 system, modulating CTX clearance. To understand CTX-HIV medication interactions, we performed a retrospective analysis of all patients (pts) diagnosed with a solid NADC who took CTX with combined antiretroviral therapy (cART). Methods: 157 pts with solid NADC were identified via a computer search at County Hospital. Adverse events (AE) during CTX in pts taking cART were assessed by chart review and graded per the NCI Common Terminology Criteria. Statistics: A Fisher's exact test was used to examine the differences in AE incidence. Results: Patients who did not take cART in conjunction with, or did not require CTX, were excluded. The number of pts analyzed for anal cancer (n=25), lung carcinoma (n=9), breast (n=7), and head and neck carcinoma (HNSCC) (n=4) represents 94% of pts taking cART with CTX in our cohort. Interestingly, Forty-two pts (50%) never received cART during therapy. All pts with anal carcinoma were treated with mitomycin/5FU/radiotherapy. 46 % of the patients taking ritonavir-based cART (6 pts of 13) developed a G4 neutropenia versus 8% (1 pt of 12) taking non-ritonavir cART (p&lt;0.07). Anemia all grades with ritonavir, 54%, versus non-ritonavir cART 16% (p&lt;0.09). All grades neutropenia for lung carcinoma while taking ritonavir was 83% versus 33% while taking non-ritonavir cART. No other correlations were identified. In this cohort, 17 pts received platinum (37%), taxanes (n=5) (11%), anthracyclines (n=5) 11%, gemcitabine (n=2) (4%), and pemetrexed (n=1). No difference in AE was noted between any CTX class, AE, and cART. Conclusions: Ritonavirinduced a 38% increase in G4 neutropenia and anemia during treatment of anal carcinoma with mitomycin/5FU. More trials including HIV-associated cancer pts are needed to assess the role of cART when given in conjunction with CTX.
Potent Inhibition of the Growth and Induction of Apoptosis of Mantle Cell Lymphoma By the Novel Anthracycline Berubicin in Vitro and in Vivo
Authors: George Tsourdinis, Hyebin Park, Luhong Sun, Izabela Fokt, Arumugam Jayakumar, Hui Zhang, Qingqing Cai, Dehui Zou, Bingliang Fang, Waldemar Priebe, Michael Wang, Liang Zhang
Journal: Blood (2014)